U.S. delivers over 25 million COVID boosters; Moderna's shot in limited supply




  • In US
  • 2022-09-20 19:32:33Z
  • By Reuters
 

(Reuters) - The United States government has sent out over 25 million of the updated COVID-19 booster shots, mostly from Pfizer/BioNTech, as production of the Moderna shot continues to ramp up, a federal health agency said on Tuesday.

Some U.S. pharmacies like CVS Health and Walgreens Boots Alliance also reported on Tuesday that government supply of Moderna's updated shot remains limited, causing appointments for the product to vary across the country.

Both CVS and Walgreens said they are working with the government to acquire more Moderna doses and have not seen any supply issues for the Pfizer/BioNTech booster.

In August, the U.S. Food and Drug Administration authorized Pfizer and Moderna's updated booster shots that target the dominant BA.4 and BA.5 Omicron subvariants, as the country prepares for a broad fall revaccination campaign.

According to the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), retail pharmacies will be receiving millions more doses of Moderna this week and that production is ramping up.

"We anticipate supply will continue to increase in the coming weeks," an ASPR spokesperson told Reuters.

Moderna said it is working closely with the U.S. government to deliver significant amounts of the updated, bivalent booster doses and anticipates that these availability constraints will be resolved in the coming days. It said it expects to ship the 70 million doses by the end of the year, as promised in its contract.

The U.S. has ordered more than 170 million updated vaccine booster shots for this fall when all individuals aged 12 and over who have already received the initial doses of the vaccine are being encouraged to receive a booster shot.

(Reporting by Mrinalika Roy in Bengaluru and Michael Erman in New York; Editing by Caroline Humer and Shailesh Kuber)

COMMENTS

More Related News

Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents
Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents

(Reuters) -Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed. Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic. Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US